26502 THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK STUDIES OF...

THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK STUDIES OF NOXAFIL® IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS – A LEADING CAUSE OF DEATH AMONG IMMUNOCOMPROMISED PATIENTS Each year more than 1.3 million hospital patients are affected by Invasive Fungal Infections (IFIs). Once these infections are established in high-risk patients, such as stem cell transplant recipients or chemotherapy patients, they are extremely difficult to treat and are often fatal. According to two landmark studies published recently in The New England Journal of Medicine, Noxafil – a potent new agent to prevent life-threatening IFIs -- significantly reduced the number of deaths due to fungal infections compared to other antifungals. Noxafil is the first and only antifungal approved to prevent the two most common types of IFIs. For more information on Noxafil, visit www.Schering-Plough.com.

» View the original video «

Google Video | January 24, 2007

Tags:. .leading. .deaths. .number. .million. .ev